Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 3/2021

Open Access 01-03-2021 | Myasthenia Gravis | Review Article

AChRAb and MuSKAb double-seropositive myasthenia gravis: a distinct subtype?

Authors: Jieni Zhang, Yin Chen, Jiaxin Chen, Xin Huang, Haiyan Wang, Yan Li, Weibin Liu, Huiyu Feng

Published in: Neurological Sciences | Issue 3/2021

Login to get access

Abstract

Introduction

This study investigated the characteristics of double-seropositive myasthenia gravis (DSP-MG) in southern China for disease subtype classification.

Methods

A case-control study was carried out in which the characteristics of DSP-MG patients (n = 17) were compared to those of muscle-specific tyrosine kinase antibody-positive (MuSK)-MG and acetylcholine receptor antibody-positive (AChR)-MG patients (n = 8 and 27, respectively). We also performed a literature review of DSP-MG patients.

Results

Compared to AChR-MG, DSP-MG had greater bulbar dysfunction (47.1% vs 18.6%, P = 0.04), higher incidence of myasthenia crisis (41.2% vs 14.8%, P = 0.04), more severe Myasthenia Gravis Foundation of America classification at maximum worsening, greater autoantibody abnormalities (70.6% vs 33.3%, P = 0.015), greater need for immunosuppressant treatment (58.8% vs 3.7%, P < 0.001), and worse prognosis with less remission (11.8% vs 55.6%, P = 0.001). There were no differences between DSP-MG and MuSK-MG patients. DSP-MG described in published reports was comparable to MuSK-MG.

Discussion

DSP-MG in southern China may be a subtype of MuSK-MG.
Literature
1.
Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023–1036CrossRef
2.
Tsonis AI, Zisimopoulou P, Lazaridis K, Tzartos J, Matsigkou E (2015) Zouvelou, et al. MuSK autoantibodies in myasthenia gravis detected by cell based assay--a multinational study. J Neuroimmunol 284:10–17CrossRef
3.
Muppidi S, Wolfe GI (2009) Muscle-specific receptor tyrosine kinase antibody-positive and seronegative myasthenia gravis. Front Neurol Neurosci 26:109–119CrossRef
4.
Guptill JT, Sanders DB (2010) Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol 23:530–535CrossRef
5.
Nakata R, Motomura M, Masuda T, Shiraishi H, Tokuda M, Fukuda T et al (2013) Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis [J]. Eur J Neurol 20:1272–1276CrossRef
6.
Shin JO, Morgan MB, Lu L, Hatanaka Y, Hemmi S et al (2012) Different characteristic phenotypes according to antibody in myasthenia Gravis [J]. J Clin Neuromuscul Dis 14(2):57–65CrossRef
7.
Diaz-Manera J, Rojas-Garcia R, Gallardo E, Juarez C, Martinez-Domeno A, Martinez-Ramirez S et al (2007) Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan’s syndrome. Nat Clin Pract Neurol 3:405–410CrossRef
8.
Yuan L, Lan C, Yi-fan Z (2015) The detection and clinical characteristics of serum positive of MuSK-Ab and double-seronegative in patients with MG. J Apoplex Nervous Dis 04:354–356
9.
Poulas K, Koutsouraki E, Kordas G, Kokla A, Tzartos SJ (2012) Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine. J Neuroimmunol 250:94–98CrossRef
10.
Zouvelou V, Zisimopoulou P, Psimenou E, Matsigkou E, Stamboulis E, Tzartos SJ (2014) AChR-myasthenia gravis switching to double-seropositive several years after the onset. J Neuroimmunol 267:111–112CrossRef
11.
Zouvelou V (2018) Double Seropositive Myasthenia Gravis: A 5-Year Follow-Up. Muscle Nerve 57:E129CrossRef
12.
Rostedt Punga A, Ahlqvist K, Bartoccioni E, Scuderi F, Marino MB, Suomalainen A et al (2006) Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes. Clin Neurophysiol 117:1434–1443CrossRef
13.
Jordan B, Schilling S, Zierz S (2016) Switch to double positive late onset MuSK myasthenia gravis following thymomectomy in paraneoplastic AChR antibody positive myasthenia gravis. J Neurol 263:174–176CrossRef
14.
Kostera-Pruszczyk A, Kwiecinski H (2009) Juvenile seropositive myasthenia gravis with anti-MuSK antibody after thymectomy. J Neurol 256:1780–1781CrossRef
15.
Rajakulendran S, Viegas S, Spillane J, Howard RS (2012) Clinically biphasic myasthenia gravis with both AChR and MuSK antibodies. J Neurol 259:2736–2739CrossRef
16.
Zouvelou V, Kyriazi S, Rentzos M, Belimezi M, Micheli MA, Tzartos SJ et al (2013) Double-seropositive myasthenia gravis. Muscle Nerve 47:465–466CrossRef
17.
Suhail H, Vivekanandhan S, Singh S, Behari M (2010) Coexistent of muscle specific tyrosine kinase and acetylcholine receptor antibodies in a myasthenia gravis patient. Neurol India 58:668–669CrossRef
18.
Saulat B, Maertens P, Hamilton WJ, Bassam BA (2007) Anti-musk antibody after thymectomy in a previously seropositive myasthenic child. Neurology 69:803–804CrossRef
19.
Wei C (2015) One cases of antibody of AChR and MuSK double seropositive myasthenia gravis. Journal of Clinical Neurology in Chinese 28:258–261
20.
Ju L, Zhiyun L, Hongxi C, Ziyan S, Huiru F, Xiaohui M, et al. West China Medical Journal in Chinese 2018; 33:696–702
21.
Al Saleh A, Cariga P (2007) Myasthenia gravis with AChR and MuSK antibodies positivity: case report. Clinical Neurophysiology 118(5):e165CrossRef
22.
Skjei KL, Lennon VA, Kuntz NL (2013) Muscle specific kinase autoimmune myasthenia gravis in children: a case series. Neuromuscul Disord 23(11):874–882CrossRef
23.
Sanders DB, Juel VC (2008) MuSK-antibody positive myasthenia gravis: questions from the clinic. J Neuroimmunol 201–202:85–89CrossRef
24.
Xin-xin F (2013) Detection and significance of anti-AchR antibodies and anti-MuSK antibodies in serum of myasthenia gravis. J. Med. Sci. Yanbian Univ 03:167–169
25.
Mingqiang L, Lu R, Yingna Z, Jie L, Hua F, Jing Z et al (2008) Clinical characteristics of AChRAb and MuSKAb double seropositive myasthenia gravis patients. Clinical Neurology and Neurosurgery 172:69–73
Metadata
Title
AChRAb and MuSKAb double-seropositive myasthenia gravis: a distinct subtype?
Authors
Jieni Zhang
Yin Chen
Jiaxin Chen
Xin Huang
Haiyan Wang
Yan Li
Weibin Liu
Huiyu Feng
Publication date
01-03-2021
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 3/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-021-05042-3

Other articles of this Issue 3/2021

Neurological Sciences 3/2021 Go to the issue

Letter to the Editor

Broadening the clinical spectrum of FUS mutations: a case with monomelic amyotrophy with a late progression to amyotrophic lateral sclerosis

Letter to the Editor

Reply to “Axonal” form of Guillain-Barré syndrome in a patient receiving oxaliplatin-based chemotherapy

Brief Communication

CIDP, CMT1B, or CMT1B plus CIDP?

COVID-19

Reassessing IVIg therapy in chronic inflammatory demyelinating polyradiculoneuropathy during COVID-19: a chance to verify the need for chronic maintenance therapy

Brief Communication

Contrast-induced encephalopathy mimicking total anterior circulation stroke: a case report and review of the literature

Letter to the Editor

Can telerehabilitation deal with cognitive disturbances in epilepsy?